ArticlePloS one2017
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- Safety, Biodistribution, and Radiation Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.European radiology · 2026Article
- Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostateEJNMMI physics · 2026Article
- The role of Choline-PET/CT in patients with recurrent prostate cancer and a negative PSMA-PET/CT.EJNMMI reports · 2026Article
- Optimizing Attenuation Correction inDiagnostics (Basel, Switzerland) · 2025Article
- Improved Positron Emission Tomography Quantification: Evaluation of a Maximum-Likelihood Scatter Scaling Algorithm.Diagnostics (Basel, Switzerland) · 2024Article
- Validation of image-derived input function using a long axial field of view PET/CT scanner for two different tracers.EJNMMI physics · 2024Article
- Quantitative and Qualitative Assessment of Urinary Activity ofMolecular imaging and biology · 2024Article
- Differential privacy preserved federated transfer learning for multi-institutionalEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Artificial Intelligence-Driven Single-Shot PET Image Artifact Detection and Disentanglement: Toward Routine Clinical Image Quality Assurance.Clinical nuclear medicine · 2023Article
- New Radiolabeled Exendin Analogues Show Reduced Renal Retention.Molecular pharmaceutics · 2023Article
- Pelvic PET/MR attenuation correction in the image space using deep learning.Frontiers in oncology · 2023Article
- Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study.EJNMMI research · 2022Article
- Data-driven, energy-based method for estimation of scattered events in positron emission tomography.Physics in medicine and biology · 2022Article
- Review
- Preclinical biodistribution and dosimetry and human biodistribution comparingEJNMMI research · 2022Article
- Prospective intra-individual blinded comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCombined positron emission tomography (PET) and magnetic resonance imaging (MRI) targeting the prostate-specific membrane antigen (PSMA) with a 68Ga-labelled PSMA-analog (68Ga-PSMA-11) is discussed as a promising diagnostic method for patients with suspicion or history of prostate cancer. One potential drawback of this method are severe photopenic (halo-) artifacts surrounding the bladder and the kidneys in the scatter-corrected PET images, which have been reported to occur frequently in clinical practice. The goal of this work was to investigate the occurrence and impact of these artifacts and, secondly, to evaluate variants of the standard scatter correction method with regard to halo-artifact suppression.
methodsExperiments using a dedicated pelvis phantom were conducted to investigate whether the halo-artifact is modality-, tracer-, and/or concentration-dependent. Furthermore, 31 patients with history of prostate cancer were selected from an ongoing 68Ga-PSMA-11-PET/MRI study. For each patient, PET raw data were reconstructed employing six different variants of PET scatter correction: absolute scatter scaling, relative scatter scaling, and relative scatter scaling combined with prompt gamma correction, each of which was combined with a maximum scatter fraction (MaxSF) of MaxSF = 75% or MaxSF = 40%. Evaluation of the reconstructed images with regard to halo-artifact suppression was performed both quantitatively using statistical analysis and qualitatively by two independent readers.
resultsThe phantom experiments did not reveal any modality-dependency (PET/MRI vs. PET/CT) or tracer-dependency (68Ga vs. 18F-FDG). Patient- and phantom-based data indicated that halo-artifacts derive from high organ-to-background activity ratios (OBR) between bladder/kidneys and surrounding soft tissue, with a positive correlation between OBR and halo size. Comparing different variants of scatter correction, reducing the maximum scatter fraction from the default value MaxSF = 75% to MaxSF = 40% was found to efficiently suppress halo-artifacts in both phantom and patient data. In 1 of 31 patients, reducing the maximum scatter fraction provided new PET-based information changing the patient's diagnosis.
conclusionHalo-artifacts are particularly observed for 68Ga-PSMA-11-PET/MRI due to 1) the biodistribution of the PSMA-11-tracer resulting in large OBRs for bladder and kidneys and 2) inaccurate scatter correction methods currently used in clinical routine, which tend to overestimate the scatter contribution. If not compensated for, 68Ga-PSMA-11 uptake pathologies may be masked by halo-artifacts leading to false-negative diagnoses. Reducing the maximum scatter fraction was found to efficiently suppress halo-artifacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.